Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care

CNE : 1
Start Date :  May 19, 2020End Date :  May 18, 2021

Duration :  60 Minutes

Organized by :   i3 Health

Specialties :   Oncology, Hematology Blood and Marrow Transplant, Nursing, Nurse Practitioner

Fees Fee :   Starting From Free

Conference Summary

Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care is organized by i3 Health.

Release Date: May 19, 2020
Expiration Date: May 18, 2021

Nursing Continuing Professional Development:

USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.0 contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Statement of Need:
Multiple myeloma (MM) is a B-cell neoplasm characterized by aberrant expansion of plasma cells within the bone marrow and extramedullary sites (eg, cortical bone). Approximately 32,270 new cases of MM are diagnosed in the United States annually and 12,830 people die of the disease. Although the tumor cells remain primarily within the bone marrow, they can cause a number of complications, including localized bone destruction, anemia, decreased immunity to infection, and kidney damage. MM is primarily considered a disease of older adults, with a median age at diagnosis of 69 years. From 1975 to 2007, the incidence increased by 11.4%, and is expected to continue to rise in conjunction with the aging population. Early diagnosis is difficult because symptoms often do not appear until the malignancy is in advanced stages. The 5-year survival rate remains only 52.2%.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Identify predictive and prognostic markers that can tailor treatment selection and goals to individual patients with MM
• Evaluate the efficacy and safety profiles of novel therapeutic strategies for newly diagnosed and relapsed/refractory MM
• Assess strategies to manage treatment-related adverse events, promote adherence to therapy, and ensure patient-centered MM care
• Learning objectives apply to all professions in the target audience. There are no prerequisites for this activity.

Beth Faiman, PhD, MSN, APN-BC, AOCN®, Nurse Practitioner, Department of Hematologic Oncology, Cleveland Clinic Taussig Cancer Center

✔Patient safety
  Patient safety
Credit Info

  • CNE : 1
Additional Info

Social Media Info :

Speaker (s)
1 Speaker(s)
Contact Us

Toll free Number

1(800) 826-2059


Chat Assistant

Live Chat